Results 1 to 10 of about 8,158 (292)
Pleiotropic effects of incretins
Indian Journal of Endocrinology and Metabolism, 2012 Drugs that augment the incretin system [glucagon like peptide (GLP) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors] represent a novel class of anti-hyperglycemic agents that have shown to improve the health and survival of beta-cells (improvement
Vishal Gupta
doaj +4 more sources
Bile acids and incretins as modulators of obesity-associated atherosclerosis [PDF]
Frontiers in Cardiovascular MedicineObesity is one of the major global health concerns of the 21st century, associated with many comorbidities such as type 2 diabetes mellitus (T2DM), metabolic dysfunction-associated steatotic liver disease, and early and aggressive atherosclerotic ...
Andrijana Kirsch +4 more
doaj +4 more sources
Pharmaceutics, 2023 Atherosclerosis is the leading cause of death worldwide, especially in patients with type 2 diabetes mellitus (T2D). GLP-1 receptor agonists and DPP-4 inhibitors were demonstrated to play a markedly protective role for the cardiovascular system beyond ...
Federico Bernardini +2 more
exaly +4 more sources
Indian Journal of Endocrinology and Metabolism, 2012 Nutrient excess results in systemic inflammation in diabetes contributing to insulin resistance, dyslipidaemia and increased cardiovascular risk. GLP-1 agonists and DPP-4 inhibitors, which are now well accepted therapies for diabetes may play a unique ...
Amitabh Hatwal
doaj +3 more sources
Endokrynologia Polska, 2021 INTRODUCTION: The effect of incretins including dipeptidyl peptidase 4 inhibitors (DPP4-Is) and glucagon-like peptide1 receptor agonists (GLP1-ras) in the treatment of type 2 diabetes increasing the risk of fracture remains controversial.
Qing-xin Kong +5 more
doaj +3 more sources
Orvosi Hetilap, 2011 The discovery of incretins − glucagon-like peptide (GLP)-1 and glucose-dependent insulinotrop peptide (GIP) −, clarification of their physiological properties as well as therapeutic application of incretin-based blood glucose lowering drugs opened new perspectives in the medical management of type 2 diabetes.
Gábor Winkler
core +4 more sources
Incretins or Anti-Incretins? A New Model for the “Entero-Pancreatic Axis” [PDF]
Hormone and Metabolic Research, 2014 The role of incretins in glucose homeostasis is well known. Yet, in recent years, the sustained weight loss and rapid glycemic control following bariatric surgery has challenged our understanding of the intestinal-pancreatic interaction. This in turn led to the introduction of metabolic surgery, an innovative medical discipline in which a surgical ...
Kamvissi, V +4 more
openaire +5 more sources
12-month effects of incretins versus SGLT2-Inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with Type-2 diabetes mellitus [PDF]
Clinical Pharmacology: Advances and Applications, 2018 Simone Perna,1 Manuela Mainardi,2 Paolo Astrone,2 Carlotta Gozzer,3 Anna Biava,1 Ruben Bacchio,3 Daniele Spadaccini,3 Sebastiano Bruno Solerte,2 Mariangela Rondanelli4 1Department of Biology, College of Science, University of Bahrain, Sakhir Campus ...
Perna S +8 more
doaj +3 more sources
Glucagon-like peptide-1 receptor agonists and the endothelium: molecular and clinical insights into cardiovascular protection [PDF]
Frontiers in MedicineEndothelial dysfunction represents the critical pathophysiological mediator linking the modern epidemics of obesity, type 2 diabetes mellitus, and cardiovascular disease.
Allegra Battistoni +5 more
doaj +2 more sources
Physiological Reports, 2019 Bariatric surgery is now the most widely used intervention for the treatment of human obesity. A large body of literature has demonstrated its efficacy in sustained weight loss and improvement in its associated comorbidities.
Isabel Casimiro +2 more
exaly +2 more sources